Growth Metrics

Amphastar Pharmaceuticals (AMPH) Long-Term Deferred Tax: 2013-2025

Historic Long-Term Deferred Tax for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $71.1 million.

  • Amphastar Pharmaceuticals' Long-Term Deferred Tax rose 33.56% to $71.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.1 million, marking a year-over-year increase of 33.56%. This contributed to the annual value of $71.1 million for FY2024, which is 33.56% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $71.1 million, which was down 0.00% from $71.1 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $71.1 million in Q4 2024 and a low of $22.0 million during Q3 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Long-Term Deferred Tax averaged around $56.2 million, with its median value being $53.3 million (2024).
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first dropped by 10.33% in 2021, then skyrocketed by 82.45% in 2023.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Long-Term Deferred Tax stood at $22.4 million in 2021, then spiked by 72.00% to $38.5 million in 2022, then skyrocketed by 38.22% to $53.3 million in 2023, then soared by 33.56% to $71.1 million in 2024, then skyrocketed by 33.56% to $71.1 million in 2025.
  • Its Long-Term Deferred Tax stands at $71.1 million for Q3 2025, versus $71.1 million for Q2 2025 and $71.1 million for Q1 2025.